Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Competitive TresibaⓇ label across the USA, Europe and Japan Profile Slide 57 TresibaⓇ label characteristics in the USA, Europe and Japanese markets USA Europe • Half-life of 25 hours and duration of action of at least 42 hours • Duration of action beyond 42 hours • Four times lower day-to-day Japan Duration of action up to 26 hours in Japanese patients Day to day variability of 20% variability vs insulin glargine Efficacy Safety Convenience • . Non-inferior HbA1c reduction Numerically greater FPG reduction Numerically lower insulin dose¹ Overall safety consistent with insulin Hypoglycaemia rates for TresibaⓇ, but not comparator • Injection any time of day Up to 80 and 160 units per injection • Non-inferior HbA1c reduction . Numerically greater FPG reduction • • Overall safety consistent with insulin Lower rate of overall and nocturnal hypoglycaemia Adjusting injection time when needed Up to 80 and 160 units per injection 1 Observed in majority of the trials changing diabetes® • Four times lower day-to-day variability vs insulin glargine • Non-inferior HbA1c reduction • Numerically greater FPG reduction • . Overall safety consistent with insulin Lower rate of nocturnal hypoglycaemia in Asian subjects In case of missed dose take as soon as possible novo nordisk

View entire presentation